ClinicalTrials.gg
Not yet recruitingNCT06402214LoQVAdSDUpdated May 7, 2024

The 'Lombard Effect' in Patients Affected by Adductor Laryngeal Dystonia

An interventional study of Lombard test in Adductor Spasmodic Dysphonia, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-07.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Adductory spasmodic dysphonia (AdSD) is a rare condition characterised by irregular and uncontrolled voice interruptions, most commonly affecting women around the age of 45. The diagnosis is clinical and usually requires evaluation by several specialists. The exact cause is not known, but a disturbance of the motor system is hypothesised, probably related to various causes such as loss of cortical inhibition or problems with sensory input.

Neuroimaging studies have shown hyperactivity in various brain regions during speech production in patients with AdSD, but it is still unclear whether this hyperactivity is due to a malfunction of auditory and somatosensory feedback or an impairment of motor programming.

Recent research indicates that patients with AdSD show excessive muscle activation during phonation, probably due to abnormal processing of auditory feedback. This suggests that intervention in the auditory system may offer new treatment opportunities.

The proposed study aims to describe the acoustic, auditory-perceptual and subjective voice and speech changes in AdSD subjects during the Quick-Lombard Test (LT), a test that assesses vocal response under noisy conditions.

02

Conditions studied

  • Adductor Spasmodic Dysphonia

Browse trials for

Keywords

  • laryngeal dystonia
  • spasmodic dysphonia
  • Lombard effect
  • auditory system
03

In context

Dysphonia

132 studies on the registry are indexed under Dysphonia; 38 are open to participants now.

This study's planned enrollment of 18 is below the median of 30 across 87 interventional studies indexed under Dysphonia.

Browse Dysphonia studies →

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 952 studies on the registry; 541 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Native Italian-speaking patients;
  • Normal hearing, hearing threshold \< 20 dB HL for frequencies from 0.5 to 4 KHz;
  • Age >18 years and \<65 years;
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Non-Italian-speaking patients.
  • Patients undergoing treatment for dystonia.
  • Previous laryngeal surgery.
  • Patient undergoing speech therapy.
  • Patient undergoing dopaminergic therapy.
  • Inability to sustain phonation of sufficient duration >3 seconds or to perform sufficient tests to assess vocal outcomes.
  • Lack of written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Case group

    patients affected by adductor laryngeal dystonia

    Other: Lombard test

  • Active comparator
    Control group

    healthy patients

    Other: Lombard test

Interventions

  • OtherLombard test

    In this study a single-subject enrolment session will be set up, with the presence of a dedicated physician for informed consent, the performance of a tonal audiometric examination and a clinical practice phoniatric examination for all enrolled subjects, the collection of voice recordings both before and during the Lombard Test (LT) and the administration of the rating scales both before and after the LT performance. For each subject, voice recordings will be made of the vowel /a/ sustained for at least four seconds with a comfortable tone and volume and of the speech obtained from the reading aloud and volume of normal conversation of a phonetically balanced text (The Desert) lasting about 1 minute, first in a silent condition and then in the presence of noise. Specifically, for the LT, each subject will be exposed to a free-fieldwhite noise of speech(SWN) administered through headphones. The intensity of the noise will be 70 dB SPL. Voice recordings will be made in a quiet room.

06

What researchers measure

Primary outcomes

  1. OMNI Vocal Effort Scale

    It is a validated instrument for the assessment of vocal effort perceived by the patient with AdSD. The OMNI-VES is a visual analogue scale 0-10 with graphic representation of vocal effort. The OMNI-VES will be administered under silent conditions and after the LT

    Time frame: At the time of enrollement

  2. Auditory-perceptual assessment

    Blinded perceptual assessment, using the Global Grading Scale - Hoarseness - Straining - Asthenia - Straining (GRBAS) 0-3 (0 = normal; 1 = mild; 2 = moderate; 3 = severe) will be performed on the recorded voice samples by two speech therapists who will not be involved in the patients' care. Each voice sample will be anonymised and randomly distributed to the assessors.

    Time frame: At the time of enrollement

  3. Maximum Phonation Time

    The maximum phonatory time (TMF) will be obtained by asking the subject to sustain the vowel /a/ as long as possible in one breath. The longest of the three attempts will be calculated as TMF in seconds. The TMF will be obtained before and during LT.

    Time frame: at the time of enrollement

  4. Average Frequency (Hz)

    The Average Frequency is the fundamental frequency of the voice (pitch) usually ranges from approximately 30-300 Hz, but this varies according to different speakers: typically males' pitch ranges from 50-180Hz and females from 80-250Hz, so we usually set the pitch range to a reasonable range of 50-400Hz for general usage

    Time frame: At the time of enrollement

  5. Maximum Frequency (Hz)

    The Maximum Frequency (Hz) is the highest frequency recorded within the voice signal

    Time frame: At the time of enrollement

  6. Maximum Intensity (dB SPL)

    The Maximum Intensity (dB SPL) parameter refers to the highest intensity of the recorded voice signal

    Time frame: At the time of enrollement

  7. Degree of Voice Interruptions (%)

    Degree of Voice Interruptions (%) is useful for the evaluation of temporary vocal interruption

    Time frame: At the time of enrollement

  8. Cepstral Peak Prominence-Smoothed (CPPS)

    Cepstral Peak Prominence-Smoothed (CPPS) has been defined as a spectrum of a spectrum, whereby an inverse Fast Fourier Transform of the natural log of a frequency-domain spectrum is applied, transforming the spectrum to the time domain. The cepstral peak (CP) is a representation of the most dominant peak in the cepstrum - normally the fundamental frequency (fo) in a type I signal. After its first applications to voice was established the method of normalizing the amplitude of the overall cepstrum using a linear regression line. When applied to the cepstrum, the level difference (dB) between the cepstral peak and the regression line at the same quefrency provides the cepstral peak prominence (CPP). The CPPS values obtained from speech and vowel tasks proved reliable in predicting overall grade of dysphonia as well as breathiness.

    Time frame: At the time of enrollement

  9. Number of Voice Interruptions

    Number of Voice Interruptions is useful for the evaluation of temporary vocal interruption

    Time frame: At the time of enrollement

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The data are paper-based

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06402214
Responsible party
Sponsor
First posted
May 7, 2024
Start date
May 1, 2024 (estimated)
Primary completion
Apr 30, 2025 (estimated)
Completion
May 1, 2025 (estimated)
Last update
May 7, 2024

Study contacts

Maria Raffaella Marchese, MD, PhD
Contact
raffaellamarchese@gmail.com
+39-3391144556
Lucia DAlatri, MD, PhD
Contact
lucia.dalatri@policlinicogemelli.it
+39-630154244
Maria Raffaella Marchese
principal investigator · Fondazione Policlinico Universitario A. Gemelli, IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion